No­vo Hold­ings, Gur­net Point Cap­i­tal en­gi­neer $462M take-pri­vate deal for an­tibi­otics play­er Paratek

No­vo Hold­ings has long in­vest­ed in com­pa­nies de­vel­op­ing an­tibi­otics. Now, it wants to take the next step: own part of a biotech that al­ready has an an­tibi­ot­ic on the mar­ket.

The Dan­ish play­er — which holds No­vo Nordisk — is join­ing hands with Gur­net Point Cap­i­tal to ac­quire Paratek and take it pri­vate in a deal val­ued at about $462 mil­lion.

“With this in­vest­ment, we ex­pand our com­mit­ment to tack­ling an­timi­cro­bial re­sis­tance, from sup­port­ing nov­el ear­ly-stage de­vel­op­ment with our RE­PAIR Im­pact Fund, late-stage de­vel­op­ment with our AMR Ac­tion Fund in­vest­ment, and now com­mer­cial­iza­tion with Paratek,” said Aleks En­gel, part­ner at No­vo Hold­ings, in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER